InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
8
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-23.3%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Huntsman Ronald Kirk, Chief Executive Officer. Insider active across 1 company, notably Vivos Therapeutics, Inc.. Aggregated, 8 reports have been recorded. Breakdown: 8 buys · 0 sell. Total volume traded: €85k. History available since 25 May 2021. The latest transaction was filed on 15 June 2023 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Huntsman Ronald Kirk
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
14,000 shares@ US$0.535.1% of flowCommon StockSEC:0001493152-23-021910:0
Canonical exit: 18 Sept 2023 (T+90)
21 shares@ US$0.500.0% of flowCommon StockSEC:0001493152-23-021751:0
Canonical exit: 13 Sept 2023 (T+90)
10,000 shares@ US$0.493.4% of flowCommon StockSEC:0001493152-23-021525:0
Canonical exit: 12 Sept 2023 (T+90)
20,000 shares@ US$0.507.1% of flowCommon StockSEC:0001493152-22-036727:0
Canonical exit: 23 Mar 2023 (T+90)
8,000 shares@ US$2.030.17% mcap13.4% of flowCommon StockSEC:0001493152-22-015773:0
Canonical exit: 29 Aug 2022 (T+90)
5,000 shares@ US$4.3121.7% of flowCommon StockSEC:0001493152-21-023354:0
Canonical exit: 20 Dec 2021 (T+90)
5,000 shares@ US$3.0015.1% of flowCommon StockSEC:0001493152-21-020536:0
Canonical exit: 15 Nov 2021 (T+90)
4,000 shares@ US$5.3820.8% of flowCommon StockSEC:0001493152-21-012901:0
Canonical exit: 23 Aug 2021 (T+90)
8 of 8 declarations
About Huntsman Ronald Kirk
Ronald Kirk Huntsman is the Chief Executive Officer of Vivos Therapeutics, Inc. In this role, he is responsible for the strategic and operational leadership of the company. Ronald Huntsman plays a key role in developing innovative therapeutic solutions and optimizing the company's performance. His expertise in management and healthcare is essential for the success of Vivos Therapeutics.
